<DOC>
	<DOC>NCT01818921</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics for certain doses of beloranib in obese subjects with Prader-Willi Syndrome.</brief_summary>
	<brief_title>An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Prader-Willi Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Prader-Willi Syndrome</mesh_term>
	<mesh_term>Overweight</mesh_term>
	<criteria>Confirmed diagnosis of PraderWilli Syndrome due to chromosome 15 microdeletion, maternal uniparental disomy, or imprinting defect BMI â‰¥25 kg/m2 Type 2 diabetes mellitus is allowed Subject must agree to stay at the group home or under supervision of the group home or site staff (i.e. no home visits) for the duration of the study Stable body weight during the past 3 months, except for during home visits Use of weight loss agents in the past 3 months Type 1 diabetes mellitus Current or anticipated chronic use of narcotics or opiates</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Beloranib</keyword>
	<keyword>ZGN-440</keyword>
	<keyword>ZGN-440 for injectable suspension</keyword>
	<keyword>ZGN-433</keyword>
</DOC>